During the past decade, Musashino Red Cross Hospital conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 12 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 9 clinical trials were completed. i.e. 112.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Musashino Red Cross Hospital" #1 sponsor was "Gilead Sciences" with 5 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Janssen Sciences Ireland UC" with 2 trials sponsored and "Associations for Establishment of Evidence in Interventions" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Musashino Red Cross Hospital" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Japan Clinical Research Support Unit(J-CRSU)" with 1 trials as a collaborator and "University Hospital Medical Information Network" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Musashino Red Cross Hospital" are "Carcinoma, Hepatocellular" (4 trials), "Advanced Hepatocellular Carcinoma" (2 trials), "HBV" (2 trials), "Hepatitis B, Chronic" (2 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "Musashino Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Musashino Red Cross Hospital" are "Drug" (18 trials), "Device" (2 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Atezolizumab" (3 trials), "JNJ-56136379" (3 trials), "Sorafenib" (3 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Musashino Red Cross Hospital" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Musashino Red Cross Hospital". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Musashino Red Cross Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Musashino Red Cross Hospital, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".